Nouscom Poster presentation at ESMO 2021
Nouscom Poster presentation at ESMO 2021, reporting the first clinical dataset from the Phase 1 trial of NOUS-209, an off-the-shelf cancer vaccine based on shared neoantigens, in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab. Data in the first six Microsatellite Instable High (MSI-H) patients are shown, demonstating safety, induction of strong ex-vivo CD8 neoantigen specific T cell responses and promising early signs of clinical efficacy with no dose limiting toxicities.
- Overman M.J. al., ESMO 2021 Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability